Podcasts about clinical trials

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Taking a photo of your food and getting an accurate carb count seemed like a pipe dream just a few years ago, but this week's guest says it's here. Snaq wants to help you get nutritional info, and then see how that food actually affects blood glucose, thanks to integrations with CGMs, insulin pumps, and activity trackers. Snaq founder Aurelian Briner explains how his wife's type 1 diagnosis inspired the company, how it all works (and who owns the data), and what's next. Learn more about Snaq here Clinical Trial with Snaq here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

For TriloTalk episode 38, Lisa Chamberlain James, Senior Partner at Trilogy, and Sudipta Chakraborty, Head of Literacy & Plain Language Center of Excellence at Biogen, talk about how to use AI in the creation of lay summaries of clinical trial results. Scalability, change management, prompting, biases, realistic attitudes, and human involvement are all touched on so listen up! 

On this episode Gil Bashe and Gregg Masters sit with Joseph Dustin, founder and principal of Dauntless E-Clinical Strategies and former Medidata executive. Dustin recounts his two-decade journey transforming clinical trials—from the dawn of electronic data capture to the age of AI-driven design—and reflects on lessons learned from the late Medidata co-founder Glenn de Vries. They explore how empathy, creativity, and human connection drive innovation in clinical research—especially as artificial intelligence reshapes trial design, digital biomarkers, and decentralized models. Dustin argues that technology succeeds only when it amplifies human insight rather than replaces it. Recorded ahead of the CNS Summit 2025, the conversation highlights community, mentorship, and the “game-on” mindset that propels the next generation of biotech and mid-market innovators. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Today's guest is Gerard Quinn, Vice President of Innovation and Informatics at ICON plc. With over 35 years of experience in clinical research services, ICON is at the forefront of leveraging artificial intelligence to revolutionise the clinical trial process. In this episode, Gerard shares invaluable insights into how AI is reshaping the landscape of clinical trials, emphasising the importance of trust, scalability and evidence of value.Topics include:0:00 From pilot purgatory to scalable, data-driven AI deployment6:53 Focusing on delivering measurable, evidence-based, and trusted AI value10:43 Ensuring leadership buy-in through transparent, stepwise AI development15:54 Why AI adoption requires cultural and process change, not just implementation18:33 How AI accelerates tasks, enhances value and improves patient outcomes22:32 Optimizing trial sites, investigators and contract processes efficiently with AI27:23 How AI evolved from novelty to expectation, requiring careful implementation31:07 Managing AI adoption costs requires defined users and evidence of value35:02 Implementing AI requires strict governance, transparency, and regulatory compliance

Bonnie Tinder is the founder and CEO of Raven Intelligence, an independent B2B peer review site that amplifies the voice of the customer. She focuses on software customers, consulting partners, and software vendors and helps identify the best partners for their needs. In this episode, she shares powerful insights from leading organizations on how AI is being used not to replace employees, but to enhance experiences, streamline operations, and drive better business outcomes through purpose-driven, human-centered deployment strategies.Episode 56 | Human-Centered AI StrategiesThe Big Themes:Augments, Not Replaces Humans: AI should enhance the human experience, not eliminate it. Real-world examples, such as Marriott's use of AI to improve the check-in process, demonstrate that AI can remove operational friction and allow frontline staff to focus on hospitality and customer engagement. In the energy sector, utilities are embedding AI into safety systems to make work more accurate and proactive. These examples show that the most successful AI deployments begin by identifying pain points in human workflows.Cultural Readiness Is Crucial for AI Success: AI adoption is not just a technical project; it is a cultural transformation. Multiple examples made it clear that even the most advanced tools can fail without the right introduction. One university CHRO compared AI implementation to sneaking vegetables into meals. By avoiding technical jargon and focusing on small improvements, they saw stronger adoption. People often resist what they do not understand, especially when it feels like a threat. Leaders who frame AI as a tool for reducing stress, reclaiming time, and increasing impact are more likely to succeed.AI Should Start with Outcomes: Real AI value begins with the business goal, not the technology itself. Companies that succeed with AI are the ones that begin by identifying the result they want to achieve. Whether it's streamlining hotel check-ins, reducing safety risks in energy infrastructure, or accelerating clinical breakthroughs, effective strategies start with specific problems. These companies ask their teams where the friction lies, and then choose tools to fix those issues. This is a shift from a technology-first mindset to an outcome-first mindset.The Big Quote: “I hope you know business people will all start to get to the point of like, yes, the nature of work is going to change. But AI is not going to spell doom and gloom for every worker on Earth. It's going to give many, many, many of them an opportunity to do better things." Visit Cloud Wars for more.

Send us a textUrologist Dr. Yaw Nyame joins Dr. Michael Koren to discuss bladder and prostate cancers. Dr. Nyame talks about his journey through college - including the choice between rock stardom and medical school - and how he got to the Fred Hutch Cancer Center in Seattle. Dr. Nyame explains symptoms, the history, and treatments for prostate and bladder cancer. He tells us "if you have blood in the urine, you definitely want to get to your primary care doctor." He also expands on gaps in cancer outcomes for Black men. Along the way, we weigh benefits and harms of PSA screening and talk honestly about sexual health after treatment.Show Note: Lynch syndrome is a genetic condition also known as hereditary nonpolyposis colorectal cancer (HNPCC). It represents an increased risk of several cancers, including colorectal, endometrial, gastric, ovarian, and pancreatic cancer. It is caused by an error in the DNA mismatch repair mechanism, which normally corrects for random insertions into the DNA code.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Scott Bradley, VP of AI and Innovation at Novartis. As the eighth largest pharmaceutical company in the world by revenue, Novartis' medicines reach millions of people worldwide. Their focus on the discovery and development of novel, breakthrough treatments sees them reimagining not just the delivery of said treatments, but the practice of medicine at large. Scott joins Emerj Editorial Director Matthew DeMello to examine how artificial intelligence is transforming trial design, operations, and patient engagement — while also reshaping industry trust and accountability. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

John Spink, Ph.D. is the Director and Lead Instructor for the Food Fraud Prevention Academy, as well as an Assistant Professor in the Department of Supply Chain Management (SCM) in the College of Business at Michigan State University (MSU). His food fraud prevention research focuses on policy and strategy to understand and prevent supply chain disruptions and to implement procurement best practices. He is widely published in leading academic journals and has helped lead national and global regulatory and standards activity. More recently, his teaching and research has expanded to supply chain disruption management and procurement best practices. Roy Fenoff, Ph.D. is an Associate Professor in the Department of Criminal Justice at The Military College of South Carolina (The Citadel). He is also a Forensic Handwriting and Document Examiner and an expert in forgery detection. Dr. Fenoff specializes in forgery and document fraud, food fraud and protection, and transnational crime. In this episode of Food Safety Matters, we speak with Drs. Spink and Fenoff [33:30] about: Their recurring workshop and certificate course for the annual Food Safety Summit on food fraud prevention What makes food fraud an urgent and misunderstood issue The intersections between food safety and food fraud Different ways to check for, catch, and trace food fraud The elements of a comprehensive food fraud vulnerability assessment Focus areas for companies trying to develop a deep enough understanding of their supply chains and end products to prevent food fraud from occurring How to implement a food fraud prevention strategy and management system, which is taught during Drs. Spink and Fenoff's annual Food Safety Summit course, and how course participants respond to and have applied these teachings within their companies What Drs. Spink and Fenoff find both meaningful and challenging about their food fraud prevention and research work. News and Resources News Color Manufacturers Sue West Virginia Over 'Unconstitutional' Food Dye Ban [7:08] California Enacts Law Defining Ultra-Processed Foods, Will Ban UPFs in Schools [14:40] Reagan-Udall Report Explores Strengthening Cross-Sector Responses to Food Safety Threats [23:09] Novel Salmonella Vaccine Shows Promise in Clinical Trial [28:57] Resources "Ultraprocessed Nation" in the New York Times' October 20, 2025 "The Morning" newsletter We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

The approach may provide better visual acuity than current optogenetic therapies in clinical trials.

While we're making progress in TREATING cancer, worldwide cancer INCIDENCE is soaring, especially among young people; New guidelines for colon cancer screening urge earlier start at age 45; Rates of peanut allergy are declining as more parents follow revised advice to introduce nuts earlier to kids; What's with all the buzz about methylene blue? Legalization and stronger pot are creating an epidemic of ER visits for uncontrolled vomiting, debilitating abdominal pain; New smart toilet gives you a report card on your poop; When Zoloft doesn't work for anxiety.

Drs. Lynce and Waks discuss advances in early-stage HER2+ breast cancer, focusing on how targeted therapies have transformed outcomes. They explore de-escalation strategies, the role of platinum drugs, insights from the COMPASS trial, and the importance of pathologic complete response in guiding treatment decisions.

Dr. Nicole Glaser is the Chief of Pediatric Endocrinology and a professor of Pediatrics at UC Davis Children's Hospital. She is recognized as an international expert in pediatric diabetic ketoacidosis (DKA), an important complication of diabetes in children. She has led many of the key multi-center studies that guide DKA management. She has also been involved in the development of several national and international guidelines for DKA management in children that guide current practice worldwide.Learning Objectives:By the end of this podcast, listeners should be able to:Describe best practices for triaging patients with DKAExplain the pathophysiology of acute cerebral edema in DKADescribe the evidence and physiologic basis for fluid selection and rate in DKA Describe the evidence supporting insulin infusion rates in pediatric DKA List best practices for lab monitoring in DKA, and how to define when a patient is ready for transition to subcutaneous insulin References: Abramo TJ, Szlam S, Hargrave H, Harris ZL, Williams A, Meredith M, Hedrick M, Hu Z, Nick T, Gonzalez CV. Bihemispheric Cerebral Oximetry Monitoring's Functionality in Suspected Cerebral Edema Diabetic Ketoacidosis With Therapeutic 3% Hyperosmolar Therapy in a Pediatric Emergency Department. Pediatr Emerg Care. 2022 Feb 1;38(2):e511-e518. doi: 10.1097/PEC.0000000000001774. PMID: 30964851.Kuppermann N, Ghetti S, Schunk J, et al. Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis. N Engl J Med. 2018;378:2275-2287.Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med. 2001;344:264-269.Bergmann KR, Abuzzahab MJ, Perepelista V, Udeogu J, Qiu L, Lammers S, Nickel A, Watson D, Kharbanda A. Improving Emergency Department Care for Children With Medium- and High-Risk Diabetic Ketoacidosis. Pediatrics. 2025 Oct 1;156(4):e2024068959. doi: 10.1542/peds.2024-068959. PMID: 40907982.UC-Davis-Health-Magazine-Fall-2019.pdfQuestions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Send us a textCardiologist Dr. Koren joins Kevin Geddings to talk about the importance of understanding what we know about patients. The cardiologist recounts a recently recorded podcast where he - with full consent - reviewed the cardiovascular infomation of a patient to give a broader understanding of what all of the numbers mean and how they can give doctors and patients insight into what's going on. Dr. Koren then makes an offer to do this for other patients to help illuminate other medical areas with experts in those fields - right here on MedEvidence!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textNebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial.Farag MM, Ghazal HAE, Abdel-Mohsen AM, Rezk MA.Eur J Pediatr. 2025 Sep 1;184(9):586. doi: 10.1007/s00431-025-06381-5.PMID: 40888971 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode of Project Synapse, we explore the innovative use of AI in veterinary oncology with Dr. Christopher Pinard. Dr. Pinard, a veterinary oncologist, discusses his journey from coding HTML in grade school to developing AI-driven solutions for cancer in pets. He shares insights on the challenges and opportunities within veterinary medicine, the impact of AI on clinical efficiency, and the future of personalized medicine for pets. We also delve into issues like regulatory challenges, the importance of context in AI models, and the potential of federated learning. If you're interested in the intersection of AI and veterinary medicine, this episode is a must-watch! 00:00 Introduction to Project Synapse 01:12 Meet Christopher Pinard: Veterinary Oncologist 01:27 The Evolution of Veterinary Specialties 02:02 Training and Clinical Trials in Veterinary Oncology 03:21 AI in Veterinary Medicine 03:48 The Intersection of Veterinary and Human Medicine 04:34 Challenges in Veterinary Medicine 05:19 Cancer Statistics in Pets 09:12 Protein Folding and AI in Drug Development 23:48 AI Scribes and Summarization in Veterinary Medicine 35:43 Guardrails to Prevent Hallucinations 36:57 Embedding Models and Knowledge Graphs 37:49 Introducing Hero: The Rationalization Engine 38:11 Grading Methodology for AI Outputs 39:18 Using Multiple Models for Fact-Checking 43:54 Extracting Data from Clinical Records 45:45 The Future of Domain-Specific AI Models 48:16 Challenges and Opportunities in Veterinary AI 50:55 Federated Learning and Bias Mitigation 55:03 The Importance of Regulation and Education 01:01:50 Starting a Veterinary AI Business in Canada 01:08:00 Future Directions in Veterinary Oncology 01:08:58 Conclusion and Farewell

Leyla Muedin, a registered dietitian nutritionist, discusses the gastrointestinal (GI) side effects commonly experienced by patients using GLP-1 medications such as Ozempic and Rybelsus. Leyla introduces a nutraceutical called Digexin, created by N-X-T-U-S-A, which has shown promise in mitigating these side effects and improving overall well-being. The episode highlights the need for patients to prioritize animal protein intake and incorporate strength training to maintain muscle mass, especially when taking GLP-1 medications. Leyla emphasizes the importance of developing healthy habits and lifestyle changes to sustain weight loss after discontinuing these drugs.

In this episode of the Flex Diet Podcast, I'm joined by Erin Silver Lee, the CEO of Flow Neuroscience. We dig into some seriously cool stuff — including Flow's recent acquisition of the Halo device, which uses non-invasive brain stimulation (TDCS) to boost both athletic and mental performance.Erin and I talk about how this tech works, what the current research says, and how it's being applied to improve focus, sleep, neuroplasticity, and overall brain health. We also get into the real-world side of things — from navigating FDA regulations to running clinical trials and shaping the future of personalized brain optimization.If you're curious about where neuroscience meets performance — and how safe, evidence-based brain stimulation might fit into the next generation of recovery and training tools — you'll want to check this one out.Sponsors:Beyond Power Voltra 1: https://www.beyond-power.com/michael13Tecton Ketone Esters: https://tectonketones.comAvailable now:Grab a copy of the Triphasic Training II book I co-wrote with Cal Deitz here.Episode Chapters:00:38 Background on Halo Device and Flow Neuroscience01:50 Acquisition and Technology Insights02:09 FDA Regulation and Consumer Approval06:02 New Device Focus and User Benefits07:29 Device Design and Usage08:45 Impact on Sleep and Mental Performance16:17 Personalization and Future Developments26:06 Focus and Concentration Benefits29:33 Navigating FDA Regulations30:35 Depression Treatment Success in Europe30:51 Challenges with Regulatory Approval31:50 Real-World Success and Halo Product Launch33:23 Navigating FDA Approval and Bias42:45 Clinical Trials and Expanding Indications51:25 Brain Health and Personal Practices55:33 Podcast Conclusion and Listener Information Flex Diet Podcasts You May Enjoy: Episode 346: From Navy SEAL to Neuroscience: Dr. Blaine Lints on Ibogaine and PerformanceYouTube: https://youtu.be/8UNGgyqBWm0 Episode 241: A New Perspective on Brain Health with Dr. Shaun KornfeldYouTube: https://youtu.be/1HcgPp6Wz7QConnect with Flow Neuroscience:Website: https://www.haloneuroscience.com/Facebook: https://www.facebook.com/halo.neuroscienceYouTube: https://www.youtube.com/@HaloNeuroscienceLinkedIn: https://www.linkedin.com/company/halo-neuroscience/Instagram: https://www.instagram.com/halo.neuro/Get In Touch with Dr Mike:Instagram: DrmiketnelsonYouTube: @flexdietcertEmail: Miketnelson.com/contact-us

Clinician-scientist Jill Helms is an expert on healing. Until about age 30, people heal easily, she says, but later on, not so well. Regenerative medicine suggests avenues for improvement, she promises. Her research focuses on understanding the physical and molecular processes of healing to design better therapies. One approach awakens “sleeper” stem cells to aid healing, a new drug in trial regenerates bone, and another avenue targets infections that appear near medical devices using gum-like tissues that create sealing barriers. In many ways, nature remains our best model for healing, Helms tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Jill HelmsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Jill Helms, a professor of surgery at Stanford University.(00:03:42) Why Study Wound HealingJill shares what led her to explore how the body repairs itself after injury.(00:04:23) How Healing WorksExplanation of physical signals, stem cells, and the stages of tissue repair.(00:07:23) Healing Declines with AgeHow healing quality and speed drop significantly after age thirty.(00:10:48) Physical vs. Biological SignalsThe biological and physical signals that work together to guide healing.(00:13:21) Regenerative MedicineTherapies designed to restore healing capacity and accelerate repair.(00:16:55) Infection and ImplantsChallenges of preventing infections around skin penetrating medical devices.(00:21:54) Nature's BlueprintUsing biological models to inspire self-renewing wound interfaces.(00:26:19)  Biomimicry and Evolutionary InsightWhat scientists are learning from animals to inform human tissue repair.(00:30:51) Future In a MinuteRapid-fire Q&A: scientific curiosity, young researchers, and supportive environments.(00:33:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Michael chats with Kathy Lee-Sepsick, CEO and Founder of Femasys. Together, they discuss the founding of Femasys and the products it offers, how Kathy has gone about raising capital for a women's health company despite a challenging lack of sector investment, the importance of gathering thorough safety data for regulatory approvals and commercialization, how Kathy envisions the global commercialization rollout for FemaSeed and FemBloc in the coming months, and much more. To learn more about Femasys and its products, visit Femasys.com.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.---TIMESTAMPS00:00 - Introduction05:09 - Challenges and Strategies in Treatment10:55 - Bladder Sparing Therapies21:41 - Practical Tips for Therapy Administration30:39 - Challenges and Considerations in Reinduction37:05 - Clinical Trials and Future Directions44:11 - Counseling Patients on Treatment Options57:36 - Concluding Thoughts and Future Outlook---RESOURCESCORE-008 Clinical Trial https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147Legend Clinical Trial:https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802CISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

In this episode of Curing with Sound, we explore a groundbreaking approach to one of medicine's toughest cancers, glioblastoma (GBM), with Michael Canney, PhD, Chief Scientific Officer at Carthera. GBM is the most aggressive form of brain cancer, notoriously hard to treat because the blood-brain barrier (BBB) blocks many life-saving drugs from reaching tumor cells. With survival rates of just one to two years, new approaches are urgently needed. Dr. Canney shares how Carthera's SonoCloud-9, an implantable, therapeutic ultrasound device, temporarily opens the BBB and enhances the delivery of circulating drugs to the brain. He also discusses the SONOBIRD clinical trial, comparing the use of Carthera's SonoCloud-9 device combined with chemotherapy to standard-of-care therapies in patients with recurrent GBM. Discussion highlights: Phase III SONOBIRD Trial: The largest clinical trial in Carthera's history, enrolling 560 patients across the United States and Europe. The trial's goal is to demonstrate a survival advantage for patients with recurrent GBM when BBB opening is combined with the delivery of carboplatin chemotherapy, as compared with standard of care. Revolutionizing Drug Delivery: How SonoCloud-9 opens the BBB to increase carboplatin concentrations five- to seven-fold, potentially unlocking the full potential of existing cancer drugs that previously couldn't reach brain tumors. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

This episode of Talking AI features an in-depth discussion with Patrick Leung, CTO and co-founder of Faro Health.The conversation explores the slow and expensive process of bringing new drugs to market through clinical trials and how AI can revolutionize this area.Patrick explains the concept of Eroom's Law and the increasing cost and complexity of clinical trials.He highlights the application of AI in clinical writing, enabling the automation of complex clinical documentation.The discussion also touches on AI's role in providing better insights, improving patient care, and the broader implications of AI in healthcare.The episode concludes with a look at the hype and reality of AI capabilities, emphasizing the need for organizations and individuals to embrace and adapt to AI innovations.--Key Moments:00:46 Challenges in Clinical Trials02:31 AI's Role in Clinical Documentation04:37 Ensuring Accuracy and Quality with AI07:40 The Future of AI in Clinical Trials12:58 Faro Health's Journey and Innovations18:25 Adapting to Advancements in AI20:14 Innovating with New AI Models21:12 Stanford AI Report Insights22:27 Healthcare Innovations and AI25:42 The Hype and Reality of AI in Healthcare28:05 The AI Hype Curve30:46 The Future of AI and Human Potential34:54 Encouragement for Aspiring Innovators--Key Links:Faro Health Inc.Connect with Patrick on LinkedInMentioned in this episode:AI Opportunity FinderFeeling overwhelmed by all the AI noise out there? The AI Opportunity Finder from HatchWorks cuts through the hype and gives you a clear starting point. In less than 5 minutes, you'll get tailored, high-impact AI use cases specific to your business—scored by ROI so you know exactly where to start. Whether you're looking to cut costs, automate tasks, or grow faster, this free tool gives you a personalized roadmap built for action.

There have been nearly 30 years of disease modifying trials for PD, but little success. Prof. Tanya Simuni breaks down clinical trial design for a heterogenous disease like PD and discusses the future goals and importance of a biological definition.

With Jean-Benoit Le Polain de Waroux, St-Jan Hospital, Brugge - Belgium, and Maarten De Smet, AZ Sint Jan, Brugge - Belgium.  Link to European Heart Journal paper Link to European Heart Journal editorial

In this heartfelt episode of the Eye Believe Podcast

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. Reza Bolouri, a memory expert, joins Dr. Michael Koren to discuss Alzheimer's, what it is, the risks, how it differs from other forms of dementia. The doctors also explore how treatment of dementia has evolved and progressed over the years from symptomatic treatments to new, disease-modifying medications that can slow the progression of Alzheimer's. They also talk about how clinical trials are exploring the next generation of Alzheimer's medications and tests which may provide preventative solutions to stop the disease before it even starts.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 1 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 1: bit.ly/3Y3ivHM Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP

Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand. Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his experience working in the hospital. We were working at Stanford, and there we were, computer scientists building a lot of internal tools for clinical trials, clinical research, as well as for the greater healthcare patient services. And that, combined with my experience trying to enroll in a clinical trial, really set us off to think deeply about how we can automate a lot of the manual workflows that exist today for patients and for providers, as well as for pharma in taking new drugs to market. Specifically, within that, we identified patient engagement and support, and prescreening to be an important part of ensuring that patients know where they're going and what to do when they're participating in these trials. And so we decided to really step out into the industry and change this process and make it an easier and more accessible experience for patients."   "I would say that having worked inside a hospital and seeing all of this lead generation or getting people educated about the trial is an important aspect, and it's being done by a lot of the recruitment vendors as well as in-house teams out there. In addition to that, a bottleneck that previously has always been there now is possible to automate with agentic AI is actually doing the work of taking all the interest from different potential patients and helping them prescreen and understand the requirements of the trials, getting them to the right site, booking their transportation, reminding them about the appointments, and scheduling that appointment."   "I would say that Grace, as we call her, is a digital staff or an AI agent - both are comparable terms to describe Grace. The difference is that Grace is trained on the trial, the requirements, and the IRB-approved script of that trial. So she really has the knowledge to be able to respond spontaneously in real time to any questions that the participant may have about the trial." #GroveAI #ClinicalTrials #PatientRecruitment #Pharma #HealthTech #DigitalHealth #AI #AgenticAI grovetrials.com Download the transcript here

Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand. Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his experience working in the hospital. We were working at Stanford, and there we were, computer scientists building a lot of internal tools for clinical trials, clinical research, as well as for the greater healthcare patient services. And that, combined with my experience trying to enroll in a clinical trial, really set us off to think deeply about how we can automate a lot of the manual workflows that exist today for patients and for providers, as well as for pharma in taking new drugs to market. Specifically, within that, we identified patient engagement and support, and prescreening to be an important part of ensuring that patients know where they're going and what to do when they're participating in these trials. And so we decided to really step out into the industry and change this process and make it an easier and more accessible experience for patients."   "I would say that having worked inside a hospital and seeing all of this lead generation or getting people educated about the trial is an important aspect, and it's being done by a lot of the recruitment vendors as well as in-house teams out there. In addition to that, a bottleneck that previously has always been there now is possible to automate with agentic AI is actually doing the work of taking all the interest from different potential patients and helping them prescreen and understand the requirements of the trials, getting them to the right site, booking their transportation, reminding them about the appointments, and scheduling that appointment."   "I would say that Grace, as we call her, is a digital staff or an AI agent - both are comparable terms to describe Grace. The difference is that Grace is trained on the trial, the requirements, and the IRB-approved script of that trial. So she really has the knowledge to be able to respond spontaneously in real time to any questions that the participant may have about the trial." #GroveAI #ClinicalTrials #PatientRecruitment #Pharma #HealthTech #DigitalHealth #AI #AgenticAI grovetrials.com Listen to the podcast here

Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the reasons you want to pay particular attention to your 2026 health insurance options. As the U.S. federal government shutdown enters its third week, we're reviewing some of the ways that the shutdown may affect someone living with MS. And we're giving you a reminder about how you can add your voice and share your story of living with MS with the FDA by participating in the Shaping Tomorrow Together initiative. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A first-hand account of an important clinical trial, open enrollment begins, and how the government shutdown may affect people with MS  :22 Open enrollment for Medicare and Marketplace enrolees begins  :22 How the federal government shutdown could affect people living with MS  4:29 Your opportunity to tell the FDA what it's like to live with MS  8:57 Jan Janisch-Hanzlik shares her experience participating in a CAR-T cell therapy clinical trial, and how the treatment has impacted her MS  11:28 Share this episode  31:38 Next week's episode  31:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/424 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 424 Guest: Jan Janisch-Hanzlik Privacy Policy

Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.

Clinical trials pave the way for new breast cancer treatments, but many patients hesitate to take part. Dr. Elkhanany breaks down what these studies really mean and why access and education make a difference. What clinical trials are and how they work for patients Why every standard medicine starts with a trial How learning and access change treatment for everyone Key Questions Answered What is a clinical trial? Why do we need clinical trials? How do clinical trials progress from phase one to phase four? Why is it often difficult to get people to participate in clinical trials? How do you address patient skepticism towards clinical trials? Who decides if a new drug’s benefit is worth its risks? How do drug approval processes in the United States differ from those in Europe? What are the potential benefits for patients who participate in clinical trials? How do you approach a patient when recommending a clinical trial, especially if standard treatments have failed? What support systems exist to help patients participate in clinical trials, especially those traveling long distances or facing financial barriers? Timestamped Overview 00:00 Understanding Clinical Trials Stages 06:10 Advancing Medicine Through Clinical Trials 07:49 Cancer Treatment Decision Challenges 12:03 Global Drug Trial Decision Process 16:31 Immunotherapy Breakthrough in Cancer Treatment 20:10 Clinical Trials: Challenges and Importance 23:52 Key Patient Advice: Second Opinions 26:01 Bridging Clinical Trial Accessibility 29:05 Advancements Reducing Breast Cancer Mortality Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Clinical trials pave the way for new breast cancer treatments, but many patients hesitate to take part. Dr. Ahmed Elkhanany returns to the show to break down what these studies really mean and why access and education make a difference. What clinical trials are and how they work for patients Why every standard medicine starts with a trial How learning and access change treatment for everyone Key Questions Answered What is a clinical trial? Why do we need clinical trials? How do clinical trials progress from phase one to phase four? Why is it often difficult to get people to participate in clinical trials? How do you address patient skepticism towards clinical trials? Who decides if a new drug’s benefit is worth its risks? How do drug approval processes in the United States differ from those in Europe? What are the potential benefits for patients who participate in clinical trials? How do you approach a patient when recommending a clinical trial, especially if standard treatments have failed? What support systems exist to help patients participate in clinical trials, especially those traveling long distances or facing financial barriers? Timestamped Overview 00:00 Understanding Clinical Trials Stages 06:10 Advancing Medicine Through Clinical Trials 07:49 Cancer Treatment Decision Challenges 12:03 Global Drug Trial Decision Process 16:31 Immunotherapy Breakthrough in Cancer Treatment 20:10 Clinical Trials: Challenges and Importance 23:52 Key Patient Advice: Second Opinions 26:01 Bridging Clinical Trial Accessibility 29:05 Advancements Reducing Breast Cancer Mortality Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals and former malaria drug developer at Walter Reed, joins the Tick Boot Camp Podcast to unpack the science and strategy behind treating babesiosis. Drawing parallels to malaria, Dow explains why tafenoquine (brand: Arakoda), FDA-approved for malaria prevention, is being studied for Babesia, how coinfections (Borrelia, Bartonella) complicate care, and why chronic illness needs a different clinical approach. He previews an upcoming Mount Sinai trial for chronic babesiosis focused on fatigue outcomes and discusses real-world diagnostics using FDA-approved blood donor screening plus PCRs from Galaxy Diagnostics and Mayo Clinic. The conversation also touches on prophylaxis concepts, immune dysregulation, and building a clearer path from anecdote to evidence for the tick-borne disease community. Guest Geoff Dow, BSc, MBA, PhD CEO & Board Member, 60 Degrees Pharmaceuticals Background: Biotechnology (Perth, Australia), PhD in malaria drug discovery, decade at Walter Reed Army Institute of Research, MBA in the U.S. Leads clinical programs exploring tafenoquine for babesiosis. Key Topics & Takeaways Malaria ↔ Babesiosis Parallels: Both are red-blood-cell parasites; acute symptoms driven by red cell destruction. Similar drug targets justify testing some anti-malarials against Babesia. Why Tafenoquine (Arakoda): An 8-aminoquinoline that induces oxidative stress in RBCs; distinct mechanism from atovaquone + azithromycin combo (current standard for acute babesiosis), potentially useful for resistance management. Chronic vs. Acute Disease: Acute babesiosis in immunocompetent patients often responds to standard care; chronic illness remains under-defined and underserved. Coinfections Are Common: Many chronically ill patients present with Borrelia, Bartonella, and Babesia together; diagnostics and treatment need to acknowledge polymicrobial reality. Upcoming Clinical Trial (Mount Sinai): Population: Chronic babesiosis with disabling fatigue, plus Babesia symptoms (e.g., air hunger, anemia) and lab evidence in the last 12 months. Regimen: 4-day loading dose then 200 mg weekly of tafenoquine for 3 months. Outcomes: Patient-reported fatigue (quality-of-life) + monthly molecular testing (FDA blood donor test, Galaxy Diagnostics PCR, Mayo Clinic PCR) during treatment and 3 months post-therapy. Goals: Demonstrate symptom improvement, assess eradication signals, and validate accessible diagnostics against an FDA-accepted assay. Prophylaxis & Post-Exposure Ideas: Animal data suggest short-course tafenoquine can eradicate early Babesia; human prophylaxis trials face feasibility and regulatory hurdles. Diagnostics Gap: Need for standardized, sensitive tools to define chronic babesiosis and track response. This trial also serves as a real-world diagnostic comparison. Immune Dysregulation & IACI: Overlap among long COVID, ME/CFS, post-treatment Lyme—shared theme of immune dysregulation with possible persistent antigen stimulation. Safety Notes: G6PD deficiency is relevant to 8-aminoquinolines; established safety database exists for malaria prevention dosing—critical as studies expand to babesiosis. Notable Quotes “You've got to put some lines in the sand—run the trial, collect data, and move the field forward.” “The best we can do for chronic disease starts with defining it—and validating the diagnostics we use to track it.” “8-aminoquinolines offer a different mechanism than current babesiosis standards—key for resistance and combinations.” Resources Mentioned Arakoda (tafenoquine): FDA-approved for malaria prevention; under study for babesiosis. Diagnostics: FDA-approved Babesia blood donor screen; Galaxy Diagnostics PCR; Mayo Clinic PCR. Organizations & Events: ILADS, Global Lyme Alliance, tick-borne disease conferences. Research Partners: Mount Sinai (NYC), Tulane University (Bartonella/Borrelia collaboration). Who Should Listen Patients with chronic Lyme or chronic babesiosis symptoms (fatigue, air hunger, anemia) Clinicians seeking updates on Babesia treatment research and diagnostics Caregivers and advocates tracking IACI and immune dysregulation science Researchers exploring antimalarial repurposing for tick-borne diseases Call to Action Subscribe to Tick Boot Camp and share this episode with someone navigating chronic tick-borne illness.

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi.   In today's episode, we're exploring the risks and rewards of participating in a clinical trial with Dr. Kathy Zackowski and Mimi Brown.  Dr. Zackowski is the Associate Vice President of Research at the National MS Society, and she's going to offer an overview of the risks and benefits that you'll want to weigh in considering participating in a clinical trial. Mimi Brown lives with primary progressive MS, and Mimi is going to share her own experience as a participant in multiple clinical trials.    This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct2 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

In this episode of Longevity by Design, our host, Dr. Gil Blander, sits down with Dylan Livingston, CEO at the Alliance for Longevity Initiatives, and Dr. Brenda Eap to explore how public policy shapes the future of aging research. Dylan and Brendan share how their team pushes for legislation that supports healthy lifespan extension, aiming to bring longevity science into the center of national health priorities.Dylan and Brendan explain why policy advocacy is crucial for securing funding for research, reducing regulatory hurdles, and establishing a clear path for new therapies. They outline recent successes, including building bipartisan support in Congress and expanding access to experimental treatments in states such as Montana. Throughout their discussion, Dylan shows how effective communication,  using stories and simple analogies, helps move longevity from the lab to lawmakers' agendas.The episode closes with practical advice for listeners. Dylan highlights the power of community, clear communication, and grassroots action as tools that help turn advanced science into real-world health gains.Episode highlights:[00:00:00]: Introduction[00:01:00]: Overview of Longevity Policy and Research Funding[00:02:00]: Backgrounds and Personal Journeys into Longevity Advocacy[00:05:00]: Inspiration and Founding of Longevity Policy Organization[00:07:00]: Scientific Training and Motivation for Policy Work[00:09:00]: Mission and Approach of Longevity Advocacy Organization[00:10:00]: Policy Advocacy's Role in Advancing Longevity Research[00:12:00]: Gaps in Funding and the Importance of Government Engagement[00:13:00]: Experiences with Policy Events and Realizations about Advocacy[00:14:00]: Early Accomplishments and Congressional Engagement[00:15:00]: Building Bipartisan Support and the Longevity Science Caucus[00:16:00]: Legislative Engagement and Policy Paper Development[00:17:00]: State-Level Policy Wins and Expansion of Right to Try Laws[00:19:00]: Rationale and Strategy for State-Level Focus[00:21:00]: Plans for Geographic Expansion of Longevity Policy Initiatives[00:23:00]: Political Climate and Opportunities with the Current Administration[00:25:00]: Shifts in Federal Attitudes Toward Longevity and Healthspan[00:27:00]: Demographics, Policy Momentum, and National Health Priorities[00:29:00]: Prevention Versus Treatment: Shifting Policy Mindsets[00:32:00]: Communicating Policy Opportunities to a Wider Audience[00:34:00]: Ensuring Longevity Policy Remains Bipartisan[00:35:00]: Intersection of Policy, Science, and Public Engagement[00:37:00]: Funding and Regulatory Challenges in Longevity Research[00:39:00]: Barriers in Clinical Trials and Policy Modernization[00:40:00]: Strategies for Communicating Longevity Science to Policymakers[00:44:00]: Framing Longevity for Policy Impact and Public Understanding[00:48:00]: Future Vision and Milestones for Longevity Policy[00:51:00]: How Individuals and Organizations Can Support Longevity Advocacy[00:55:00]: Practical Longevity Advice and Episode ConclusionWe Appreciate You!As a token of our gratitude, we're excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcastFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

If you've ever felt alone in the healthcare maze, this episode is here to remind you: your story matters, and you are not alone. Kavita Bouknight shares how her personal health journey and family experiences inspired her mission to make healthcare information more accessible, and how she's leveraging technology through her company's program, SPARK, to bridge crucial communication gaps between patients and providers. The conversation explores the needs and future of women's health, the entrepreneurial path, and the importance of advocating for yourself and others in today's complex medical landscape.    TIMESTAMPS: 00:00 "Match Health Collective Founder Interview" 03:40 "Navigating Care in Sandwich Generation" 08:01 Navigating Stressful Situations 10:10 Navigating Healthcare Isolation 16:01 Patient Engagement in Clinical Trials 19:48 Advocating for Clear Breast Health 22:17 Dense Breast Tissue Awareness 25:49 Take the Leap and Evolve 27:18 Entrepreneurial Evolution and Vision 29:51 Naming Expertise Transforms Business 34:06 Boosting Women's Health Awareness 38:21 Feeling Alone Despite Support 39:39 Expressing Gratitude and Support   LEARN MORE: The Clear Pathways Program: https://www.breastdensitysummit.org/ MAKE A DONATION: https://www.paypal.com/donate?hosted_button_id=NJMF86A8Y9RJQ Women's Health Advocates: https://womenshealthadvocates.org/   With a focus on health innovation and high-impact marketing, Kavita Bouknight is a trusted advisor to venture-backed startups and publicly traded healthcare organizations, bringing over 20 years of experience in strategy and go-to-market execution. She is the Founder and CEO of Match Health Collective, a full-service marketing agency that helps medical device and life science companies build brands, accelerate clinical adoption, and engage patients and physicians. She also leads Match Health Academy, which develops programs and tools to drive meaningful engagement and make complex health information more accessible through video and text-based communication. FOLLOW KAVITA:  Website: https://matchhealth.com Kavita LinkedIn: https://linkedin.com/in/kavitabouknight/ Match Health Collective LinkedIn: https://www.linkedin.com/company/match-health-collective/?viewAsMember=true   FOLLOW LISA: https://www.linkedin.com/in/lisamalianorman/ https://www.instagram.com/lisamalia.evoke/  

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.